SALT LAKE CITY – July 26, 2023 –– bioMérieux, a world leader in in vitro diagnostics, infectious disease management, and service and system performance, was recently awarded nine IMV ServiceTrak™ Clinical Laboratory Awards in the categories of Immunoassay, ID/AST, and Blood Culture excellence. The awards recognize bioMérieux’s distinction in comprehensive service and system performance.
IMV, part of Science and Medicine Group, is the leading market research and business intelligence provider to the laboratory diagnostic industry. IMV ServiceTrak Clinical Awards are presented each year to the manufacturers with the highest satisfied responses, representing the best in customer satisfaction, performance, and service.
This year bioMérieux was honored with nine awards, a sweep across Immunoassay, ID/AST and Blood Culture where laboratory professionals have rated bioMérieux’s technology platforms, system performance and service to be the best in the following categories:
- Immunoassay:
- Best Service
- Best Customer Satisfaction
- Best System Performance
- ID/AST:
- Best Service
- Best Customer Satisfaction
- Best System Performance
- Blood Culture:
- Best Service
- Best Customer Satisfaction
- Best System Performance
These awards symbolize bioMérieux’s commitment to public health, providing increasingly sophisticated diagnostic testing solutions and fast, accurate and actionable information to assist physicians in the diagnosis, treatment and care of patients.
The company provides extensive technical and professional training to its team members, thus ensuring exceptional service as part of bioMérieux’s culture. The awards are the result of a relentless focus of the collective functions within bioMérieux driving customer centricity, continuously improving its products and service delivery model.
“We are thrilled that bioMérieux has received significant recognition and multiple awards from IMV ServiceTrak™ for the sixth consecutive year. This demonstrates the sustained commitment to providing an outstanding customer experience throughout the lifecycle of their clinical instrumentation. Our commitment to deliver innovative diagnostic systems, service, and customer satisfaction further supports the successful activation of antimicrobial stewardship efforts, as well as bioMérieux’s essential role in the betterment of public health.”
BIOMÉRIEUX GAME CHANGERS FOR 60 YEARS
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software, and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products. www.biomerieux.com.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP